Bronchitis Treatment Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| CAGR | 3.60 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Market Concentration | Medium |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Bronchitis Treatment Market Analysis
The bronchitis treatment market is expected to grow at a CAGR of 3.6% over the forecast period (2022-2027).
The onset of the COVID-19 pandemic has led to a reduction in the number of patient visits that reduced the number of patients opting for bronchitis treatment, thereby impacting the market growth. For instance, as per a September 2020 published article titled, "Reduction in ambulatory visits for acute, uncomplicated bronchitis: an unintended but welcome result of the coronavirus disease 2019 (COVID-19) pandemic", the COVID-19 pandemic, while challenging for so many other aspects of antimicrobial stewardship, has led to an overall net reduction in ambulatory adults seeking care for bronchitis in the health system and has resulted in a dramatic reduction in antibiotic prescriptions for the condition. As a result, the impact of COVID-19 on the market was adverse during the initial phase of the pandemic.
Further, the major factors fueling the market's growth are the rise in the geriatric population with an augmented incidence of bronchitis, the growing prevalence of chronic obstructive pulmonary disease (COPD), an upsurge in the smoking populace, and rising levels of chemical pollutants.
The increased prevalence of COPD is a major factor driving the market growth. For instance, as per the House of Commons 2022, NHS Digital data shows that in 2020-2021, approximately 1.17 million people in England have been diagnosed with COPD, which is around 1.9% of the population. Also, as per a June 2021 update by the World Health Organization (WHO), chronic obstructive pulmonary disease (COPD) is the third leading cause of death worldwide, causing 3.23 million deaths in 2019. Thus, the increasing burden of COPD is leading to increasing demand for bronchitis treatment, as chronic bronchitis is one of the most common conditions leading to COPD, thereby contributing to the market growth.
However, the patent expiry of key drugs is a major factor hindering the bronchitis treatment market's growth.
Bronchitis Treatment Market Trends
This section covers the major market trends shaping the Bronchitis Treatment Market according to our research experts:
The Bronchodilators Segment is the Expected to Show a High Growth During the Forecast Period
By class of drugs, the bronchodilator segment is anticipated to hold a major share of the market. Bronchodilators are drugs that open the airway passages and are also used for expanding the windpipe, thus improving the breathing of individuals suffering from lung infections, bronchial asthma, and chronic obstructive pulmonary disease (COPD). Bronchodilators are the first-line medication for the treatment of bronchitis for clearing the airway obstruction, which is an essential parameter in chronic bronchitis to ease the breathing in patients.
Further, the major factors, such as the increasing incidence of respiratory diseases, the rising prevalence of smoking, and the rising product approvals, are driving the growth of the market segment. Therefore, as the number of respiratory diseases is increasing, the demand for bronchodilators is all set to increase. For instance, as per a February 2022 article published by the National Center for Bio, titled "Acute Bronchitis", it is estimated that every year, 5% of the general population reports an episode of acute bronchitis, accounting for more than 10 million office visits annually. Thus, the growing burden of bronchitis is increasing the demand for bronchitis treatment, thereby contributing to the market growth.
In addition, several market players are engaged in the implementation of strategic initiatives, thereby contributing to market growth. For instance, in February 2022, the United States Food and Drug Administration (USFDA) approved Lupin Limited's generic form of Brovana (arformoterol tartrate) for treating bronchoconstriction in people with chronic obstructive pulmonary disease (COPD). The active agent in Brovana is a bronchodilator, a substance that prompts the airways to relax and widen, thus lessening bronchoconstriction.
Thus, due to the above-mentioned developments, the market is expected to witness significant growth over the forecast period.
North America Dominates the Market and is Expected to do Same in the Forecast Period
Within North America, the United States has held the major share of the bronchitis treatment market.
This is due to factors such as the rising incidence of bronchitis and an increasing trend of smoking in the young generation along with an increasing number of strategic initiatives by the market players. For instance, as per a February 2022 update by the Centers for Disease Control and Prevention (CDC), 5% of the adults in the United States were diagnosed with chronic obstructive pulmonary disease (COPD), emphysema, or chronic emphysema in 2020. Thus, as COPD is associated with bronchitis, there is a significant demand for bronchitis treatment in the country, thereby contributing to the market growth.
Additionally, several market players are engaged in the implementation of strategic initiatives, thereby contributing to market growth. For instance, in June 2021, Lupin launched the generic inhalation product Arformoterol to treat chronic bronchitis in the United States market. Such developments are anticipated to fuel the development of more such products and their approval for the treatment of bronchitis in the country, which will further boost the market growth in the coming period.
Thus, due to the above-mentioned developments, the market is expected to witness significant growth over the forecast period.
Bronchitis Treatment Industry Overview
The bronchitis treatment market is moderately competitive and consists of several major players. Some of the companies which are currently dominating the market are AstraZeneca PLC, Novartis AG, GlaxoSmithKline PLC, Dr. Reddy's Laboratories Ltd, Melinta Therapeutics, Sanofi SA, Boehringer Ingelheim International GmbH, and Pfizer Inc.
Bronchitis Treatment Market Leaders
-
Sanofi S.A
-
Lupin Limited
-
Cadila Healthcare Limited
-
Boehringer Ingelheim International GmbH
-
GlaxoSmithKline
*Disclaimer: Major Players sorted in no particular order
Bronchitis Treatment Market News
- In February 2022, Zydus, a part of Cadila Healthcare, revealed that its United States subsidiary had received final approval from the US Food and Drug Administration to market roflumilast tablets in the strength of 500 mcg and tentative approval for roflumilast tablets. The tablets are indicated as a treatment to reduce the risk of chronic obstructive pulmonary disease (COPD) exacerbations in patients with severe chronic obstructive pulmonary disease (COPD) associated with chronic bronchitis and a history of exacerbations.
- In September 2021, Lincoln Pharmaceuticals Ltd acquired a facility in India that makes antibiotics used in the treatment of pneumonia and bronchitis.
Bronchitis Treatment Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Rise in the Geriatric Population with Increased Incidence of Bronchitis
- 4.2.2 Increased Prevalence of COPD Cases
- 4.2.3 Increased Smoking and Rising Levels of Chemical Pollutants
-
4.3 Market Restraints
- 4.3.1 High Cost and Strict Regulation for Drug Approval
-
4.4 Porter's Five Forces Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD million)
-
5.1 By Class of Drugs
- 5.1.1 Antibiotics
- 5.1.2 Anti-inflammatory Drugs
- 5.1.3 Bronchodilator
- 5.1.4 Other Drugs
-
5.2 By Type
- 5.2.1 Acute Bronchitis
- 5.2.2 Chronic Bronchitis
-
5.3 By End User
- 5.3.1 Hospital Pharmacies
- 5.3.2 Retail Pharmacies
- 5.3.3 Other End Users
-
5.4 By Geography
- 5.4.1 North America
- 5.4.1.1 United States
- 5.4.1.2 Canada
- 5.4.1.3 Mexico
- 5.4.2 Europe
- 5.4.2.1 Germany
- 5.4.2.2 United Kingdom
- 5.4.2.3 France
- 5.4.2.4 Italy
- 5.4.2.5 Spain
- 5.4.2.6 Rest of Europe
- 5.4.3 Asia-Pacific
- 5.4.3.1 China
- 5.4.3.2 Japan
- 5.4.3.3 India
- 5.4.3.4 Australia
- 5.4.3.5 South Korea
- 5.4.3.6 Rest of Asia-Pacific
- 5.4.4 Middle-East and Africa
- 5.4.4.1 GCC
- 5.4.4.2 South Africa
- 5.4.4.3 Rest of Middle-East and Africa
- 5.4.5 South America
- 5.4.5.1 Brazil
- 5.4.5.2 Argentina
- 5.4.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 AstraZeneca PLC
- 6.1.2 Novartis AG
- 6.1.3 GlaxoSmithKline PLC
- 6.1.4 Dr. Reddy's Laboratories Ltd
- 6.1.5 Sanofi SA
- 6.1.6 Boehringer Ingelheim International GmbH
- 6.1.7 Pfizer Inc.
- 6.1.8 Melinta Therapeutics
- 6.1.9 Lupin Limited
- 6.1.10 Cadila Healthcare Limited
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityBronchitis Treatment Industry Segmentation
As per the scope of the report, bronchitis is an inflammation of the lining of bronchial tubes, which is associated with coughing up thickened mucus, which can be discolored. The bronchitis treatment market is segmented by class of drugs (antibiotics, anti-inflammatory drugs, bronchodilators, and other drugs), end user (hospital pharmacies, retail pharmacies, and other end users), type (acute bronchitis and chronic bronchitis), and geography (North America, Europe, Asia-Pacific, Middle East, and Africa and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (in USD million) for the above segments.
| By Class of Drugs | Antibiotics | |
| Anti-inflammatory Drugs | ||
| Bronchodilator | ||
| Other Drugs | ||
| By Type | Acute Bronchitis | |
| Chronic Bronchitis | ||
| By End User | Hospital Pharmacies | |
| Retail Pharmacies | ||
| Other End Users | ||
| By Geography | North America | United States |
| Canada | ||
| Mexico | ||
| By Geography | Europe | Germany |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Rest of Europe | ||
| By Geography | Asia-Pacific | China |
| Japan | ||
| India | ||
| Australia | ||
| South Korea | ||
| Rest of Asia-Pacific | ||
| By Geography | Middle-East and Africa | GCC |
| South Africa | ||
| Rest of Middle-East and Africa | ||
| By Geography | South America | Brazil |
| Argentina | ||
| Rest of South America |
Bronchitis Treatment Market Research FAQs
What is the current Global Bronchitis Treatment Market size?
The Global Bronchitis Treatment Market is projected to register a CAGR of 3.60% during the forecast period (2024-2029)
Who are the key players in Global Bronchitis Treatment Market?
Sanofi S.A, Lupin Limited, Cadila Healthcare Limited, Boehringer Ingelheim International GmbH and GlaxoSmithKline are the major companies operating in the Global Bronchitis Treatment Market.
Which is the fastest growing region in Global Bronchitis Treatment Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Global Bronchitis Treatment Market?
In 2024, the North America accounts for the largest market share in Global Bronchitis Treatment Market.
What years does this Global Bronchitis Treatment Market cover?
The report covers the Global Bronchitis Treatment Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Global Bronchitis Treatment Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Bronchitis Treatment Industry Report
Statistics for the 2024 Bronchitis Treatment market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Bronchitis Treatment analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
